Median OS in patients with residual tumour was 19.5 versus 16.7 months , ( HR , 0.90 ; 95 % CI , 0.52-1 .57 ; P = 0.7061 ) , for patients without 23.3 versus 21.0 months ( HR , 0.77 ; 95 % CI , 0.41-1 .44 ; P = 0.4068 ) .